Report of the 2006 APhA House of Delegates.
D000970:Antineoplastic Agents; D001294:Attitude to Health; D001557:Benzenesulfonates; D003266:Continuity of Patient Care; D003469:Culture; D004196:Disease Outbreaks; D004512:Education, Pharmacy; D006801:Humans; D013287:Illicit Drugs; D009980:Influenza A virus; D007251:Influenza, Human; D007397:Internship, Nonmedical; D016347:Medical Records Systems, Computerized; D009536:Niacinamide / Q000031:analogs & derivatives; D004366:Nonprescription Drugs; D004364:Pharmaceutical Preparations / Q000145:classification; D010594:Pharmacies; D010671:Phenylurea Compounds; D011640:Public Policy; D011725:Pyridines; D012957:Societies, Pharmaceutical; D000077157:Sorafenib; D014029:Tobacco Use Disorder
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D013287:Illicit Drugs; D004366:Nonprescription Drugs; D004364:Pharmaceutical Preparations; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib